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ABSTRACT
T-cell receptor (TCR) gene transfer redirects T cells to target
intracellular antigens. However, the potential autoreactivity gener-
ated by TCRmispairing and occurrence of graft-versus-host disease
in the allogenic setting due to the retention of native TCRs remain
major concerns. Natural killer T cells (NKT) have shown promise as
a platform for adoptive T-cell therapy in cancer patients. Here, we
showed their utility for TCR gene transfer. We successfully engi-
neered and expanded NKTs expressing a functional TCR (TCR
NKTs), showing HLA-restricted antitumor activity in xenogeneic
mouse models in the absence of graft-versus-mouse reactions. We
found that TCR NKTs downregulated the invariant TCR (iTCR),
leading to iTCRþTCRþ and iTCRTCRþ populations. In-depth
analyses of these subsets revealed that in iTCRTCRþ NKTs, the
iTCR, although expressed at the mRNA and protein levels, was
retained in the cytoplasm. This effect resulted from a competition
for binding to CD3 molecules for cell-surface expression by the
transgenic TCR. Overall, our results highlight the feasibility and
advantages of using NKTs for TCR expression for adoptive cell
immunotherapies. NKT-low intrinsic alloreactivity that associated
with the observed iTCR displacement by the engineered TCR
represents ideal characteristics for “off-the-shelf” products without
further TCR gene editing.
Introduction
The role played by cytotoxic T cells in tumor control has been
recognized for years (1), but the clinical utility of their adoptive transfer
has remained elusive due to the low frequency of high-avidity, tumor-
specific T cells naturally circulating in peripheral blood (2). Advances
in gene engineering have facilitated the introduction of tumor-antigen
specificity in polyclonal T cells via expression of ectopic T-cell
receptors (TCR; ref. 3). Using this strategy, clinically relevant numbers
of TCR-redirected T cells for adoptive transfer can be generated and
have produced encouraging clinical results (4, 5).
Despite the clinical success, a major issue of the TCR technology
remains the expression of both the ectopic and endogenous TCR
chains within the same T cell. This phenomenon can cause compe-
tition for binding to CD3 molecules, resulting in a reduced expression
of the transgenic TCR (6) and TCR mispairing between the endog-
enous and transgenic TCR chains, causing potential autoreactivity (7).
The retention of functional endogenous TCRs may exacerbate graft-
versus-host disease (GvHD) if these cells are used as an allogeneic
product (8).
Several strategies have been developed to enhance TCR transgenic
expression, such as the inclusion of a codon-optimized sequence (9),
the addition of extra disulfide bonds to the transgenic TCR chains (10),
the introduction of murine residues in the TCR constant region
domain (11), and the replacement of key amino acids in the framework
of the variable region (3, 12). siRNA gene silencing (13) and TCR gene
editing (14) have been explored to knockdown the endogenous
receptor of T cells for replacement with a tumor-specific TCR.
However, siRNA-mediated TCR knockdown is generally suboptimal,
and the scale-up of gene editing for clinical use remains challenging
and of unknown safety profile.
We thus have explored the use of natural killer T cells (NKT) as a
TCR-based cell platform to overcome the issues associated with TCR
engineering in T cells. Type 1 NKTs are an evolutionarily conserved
subset of innate lymphocytes characterized by expression of the
invariant TCR a-chain Va24-Ja18 and reactivity to glycolipids pre-
sented by the monomorphicMHC class I–like molecule CD1d (15). In
humans, the invariant TCR (iTCR) Va24-Ja18 chain is paired almost
exclusively withTCRVb11 (TRBV25-1) chains (16).We reasoned that
the limited repertoire of the iTCR and its CD1d restriction should
minimize, if not eliminate, both the TCR mispairing phenomena and
the risk of GvHD when NKTs express a tumor-specific TCR. Here, we
showed the successful TCR engineering, expansion, and HLA-
restricted antitumor activity of TCR-redirected NKTs, and we dis-
sected the mechanism by which the transgenic TCR displaces the
endogenous iTCR from the cell surface of engineered NKTs.
Materials and Methods
Cell lines
The tumor cell lines SK-MEL-5 and M14 (melanoma), T2 (TAP
transporter deficient), SupT1 (CD3þTCR), and 293T cells were
obtained from the ATCC between 2015 and 2018. The tumor cell
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(200 IU/mL). In selected experiments, NKTs, CD8þ, and unselected
T cells were isolated from the same buffy coat. T cells were positively
(LS column,Miltenyi Biotech) selected using CD8-specificmicrobeads
(Miltenyi Biotech). Unselected T cells andCD8þT cells were activated,
transduced, and expanded in complete medium with IL7 (10 ng/mL,
PeproTech) and IL15 (5 ng/mL, PeproTech) as previously
reported (23). Briefly, T cells were activated on anti-CD3 (1 mg/mL,
Miltenyi Biotech) and anti-CD28 (1 mg/mL, BD Biosciences) 24-well
coated plates. At day 2, T cells were transduced in retronectin
(7 mg/mL) 24-well coated plates. On day 10, T cells were stimulated
with peptide-loaded (20 mmol/L) and irradiated (80 Gy) artificial
antigen-presenting cells (aAPC) consisting of K562 cells expressing
CD40L, CD80, OX40L, and theHLA-A02molecules (17) at an aAPC:
T-cell ratio of 1:4, and further expanded using IL7 (10 ng/mL) and IL15
(5 ng/mL) for 10 days. In selected experiments, NKTs were cotrans-
duced with retroviral vectors encoding the CD8a or the CD3 complex.
Immunophenotyping and flow sorting
T and NKT cells were stained with antibodies (Ab) against CD3
(APC-H7, clone SK7), CD62L (BV605, clone DREG-56), PD-1 (PE-
Cy7, clone EH12.1), LAG3 (PE, clone T47-530), TIM3 (BV711, clone
7D3), CD45 (APC, clone 2D1), CD4 (PE-Cy7, clone SK3), and CD8
(Alexa Fluor 700, clone RPA-T8) from BD Biosciences. Tumor cells
and aAPCs were stained with Abs against HLA-A2 (PE, clone BB7.2)
and CD276 (BV421, clone 7-517) from BD Biosciences. The purity of
NKTs was assessed by staining the cells with a tetramer specific for the
iTCR (PE-conjugated human CD1d tetramer loaded with aGalCer;
ProImmune) and the PE-conjugated Ab specific for TCR Va24 chain
(anti-iNKT, clone 6B11, from BD Biosciences). The expression of the
Tyr-TCR in NKTs was assessed using a Tyr-TCR-specific pentamer
(Pro5 MHC Pentamer A02:01 YMDGTMSQV; ProImmune) fol-
lowed by the staining with the Pro5 Fluorotag APC (ProImmune).
NKT transduction efficiency with ectopic TCRs was assessed with an
FITC-conjugated Ab specific for the TCR b12 chain (for the Tyr-TCR
and MART-1-TCR; Beckman Coulter) or the TCR b14 chain (for the
PRAME-TCR; Beckman Coulter), or stained with an APC-conjugated
Ab specific for themurine TCR constant b chain (for the Sur-TCR; BD
Biosciences). Data acquisition was performed on a BD FACSCanto II
or BD LSRFortessa using the BD FACS-Diva software. Data analyses
were performed with the FlowJo software. To count the number of
CD3 and iTCR molecules expressed from NKTs, we used the PE
Fluorescence Quantitation Kit (BD Quantibrite). In selected experi-
ments, NKTswere costainedwith an anti-iTCR tetramer and anti-Tyr-
TCR pentamer, and the iTCRþTyr-TCR, iTCRTyr-TCRþ, and
iTCRþTyr-TCRþ NKTs were sorted using a FACSAria II at the Flow
Cytometry Core Facility (UNC, Chapel Hill). After sorting, cells
(purity >96%) were kept in culture overnight in complete media and
IL2 (200 IU/mL) before performing the functional assays.
51Cr-release assay
The cytotoxic activity of NKTs and CD8þ T cells was evaluated
using a standard 5-hour 51Cr release assay (17). In brief, 5  103 51Cr
(PerkinElmer)-labeled target cells [HLA-A2þ mismatched phytohe-
magglutinin (PHA) blasts; ref. 24; M14-wt, M14-A2, C8161, and SK-
MEL-5) per well were plated in triplicate in a 96-well plate (v bottom)
with different ratios (40:1, 20:1, 10:1, and 5:1) of effector cells and
incubated for 5 hours at 37C. The supernatant was collected and
analyzed with a gamma-counter (PerkinElmer). HLA-A2þ (PHA)
blasts were incubated for 2 hours at 37C with specific peptides (100
nmol/L, YMDGTMSQV for the Tyr-TCR or ELAGIGILTV for the
MART-1-TCR) and washed twice with complete medium. Target cells
line C8161 (melanoma) was obtained in 2016 from the tissue culture 
facility at University of North Carolina, Chapel Hill (TCF, UNC-CH). 
K562 cells were previously established as described by Quintarelli and 
colleagues (17). All cells were maintained in culture with the appro-
priate media, either RPMI-1640 (Gibco), DMEM (Gibco), or IMDM 
(Gibco) supplemented with 10% FBS (Sigma), 1% L-glutamine 
(Gibco), and 1% penicillin–streptomycin (Gibco) in a humidified 
atmosphere containing 5% CO2 at 37C. The M14 cell line was 
transduced with an SFG gamma retroviral vector encoding the 
HLA-A20201 molecule (17) to obtain the M14-A2 cell line upon 
cell sorting. SK-MEL-5, M14-wild-type (wt), and M14-A2 cells were 
transduced with an SFG gamma retroviral vector encoding the firefly 
luciferase gene and the fusion protein enhanced GFP (eGFP-FFluc; 
ref. 18). Cells were kept in culture for less than 6 consecutive months, 
after which aliquots from the original expanded vial were used. All 
tumor cell lines were routinely tested to exclude contamination with 
Mycoplasma and assessed for the expression of transgenes (such as 
HLA-A2, CD40L, CD80, OX40L, and eGFP) and tumor markers by 
flow cytometry to confirm identity.
Retroviral constructs and generation of retroviral supernatants 
Retroviral supernatants were prepared by transient transfection of 
293T cells (17) and used to transduce T cells and NKTs (isolated as 
stated below). The HLA-A2–restricted TCRs specific for Tyrosi-
nase368-376 (Tyr-TCR recognizing the YMDGTMSQV peptide) and 
MART-126-35 (MART-1-TCR recognizing the ELAGIGILTV peptide) 
were obtained from Frankel and colleagues (19) and were cloned into 
the SFG retroviral vector (20). The HLA-A2–restricted survivin-
specific TCR (Sur-TCR recognizing the LMLGEFLKL peptides 96–
104) and the HLA-A2–restricted PRAME-specific TCR (PRAME-
TCR recognizing the ALYVDSLFFL peptide p300) are previously 
described (21). The human CD8a cDNA (NM_001768) was cloned 
into the SFG retroviral vector. The human CD3 complex (CD3d-2A-
CD3g-2A-CD3e-2A-CD3z) was designed as previously reported (6) 
and synthetized from Geneart and cloned in the SFG retroviral vector.
NKT and T-cell isolation, transduction, and in vitro expansion
Buffy coats from healthy volunteer blood donors were purchased 
from the Gulf Coast Regional Blood Center (Houston, TX). Peripheral 
blood mononuclear cells (PBMC) were isolated by Lymphoprep 
(Accurate Chemical and Scientific Corporation) density gradient 
centrifugation, according to the manufacturer's protocol. NKTs were 
purified from PBMCs using anti-iNKT microbeads (Miltenyi Biotech). 
NKTs were cultured in complete medium, consisting of 45% Click's 
medium (Irvine Scientific), 45% RPMI-1640 (Hyclone), 10% FBS 
(Hyclone), 1% L-glutammine (Gibco), and 1% penicillin–
streptomycin (Gibco). Upon NKT-positive selection (LS column, 
Miltenyi Biotech), the negative fraction was used as feeder cells after 
irradiation (40 Gy, RS-2000 Biological System). For the first stimu-
lation (S1), feeder cells were used once at day 0 at the PBMC:NKT ratio 
of 10:1. a-Galactosylceramide (aGalCer, 100 ng/mL, Diagnocine LLC) 
was added at day 0 and IL2 (200 IU/mL, STEMCELL Technologies) 
was added at days 0, 2, and 4. NKTs were transduced in retronectin 
(Takara, 7 mg/mL) 24-well coated plates (22) at day 6 when the NKT 
purity was more than 85%, and cells were restimulated with irradiated 
feeder cells, at the PBMC:NKT ratio of 5:1 (S2). The feeder cells were 
loaded with the peptide specific for each TCR (20 mmol/L, 
YMDGTMSQV for the Tyr-TCR, ELAGIGILTV for the MART-1-
TCR, or ALYVDSLFFL for the PRAME-TCR from Genemed Synthe-
sis) and aGalCer (100 ng/mL) in the presence of IL2 (200 IU/mL). 
NKTs were then further expanded for 10 days in the presence of IL2
protein lysates were separated by Mini-PROTEAN TGX Stain-Free
Gels (Bio-Rad) electrophoresis. After protein transfer, membranes
were incubated with 3 mL of anti-tyrosinase (Thermo Fisher, clone
T311) or 15 mL of anti-MART-1 (Invitrogen, clone M2-7C10). After
washes, membranes were incubated with 3mL ofHRP-conjugated goat
anti-mouse IgG (HþL) secondary Ab (Invitrogen). Staining for
b-actin (Santa Cruz Biotechnology) was used as loading control.
Membranes were developed with SuperSignal West Femto Maximum
Sensitivity Substrate (Thermo Scientific).
Cocultures and ELISAs
NKTs and CD8þT cells (105 cells/well) were cocultured with tumor
cell lines (M14-wt, M14-A2, C8161, or SK-MEL-5; 105 cells/well) at an
effector-to-target (E:T) ratio of 1:1 in 24-well plates, in complete
medium, in the absence of cytokines. After 3 days of culture, cells
were harvested and stained for CD3 (APC-H7, clone SK7 from BD
Biosciences) and CD276 (BV421, clone 7-517 from BD Biosciences)
monoclonal Abs (mAb) to detect T cells and tumor cells, respectively.
Percentage of residual tumor cells in culture were enumerated by flow
cytometry. NKTs (105 cells/well) were also cocultured with HLA-A2þ
T-cell blasts loaded with the YMDGTMSQV peptide (100 nmol/L) at
an E:T ratio of 1:1 or activated with 10 mL of anti-Va24 (clone 6B11,
from BD Biosciences) in 1 mL of complete medium in the absence of
cytokines. Culture supernatants were harvested after 24 hours of
culture and IFNg measured in 100 mL of supernatant with the DuoSet
Human IFNg ELISA kit (R&D Systems). Data acquisition was per-
formed on a Synegrgy2 microplate reader (BioTek) using the Gen5
software.
ELISpot assay
The IFNg ELISpot assaywasperformedas previously described (17).
Briefly, 2 104 NKTs or CD8þT cells per well were plated in triplicate
and then stimulated with 2 104 T2 cells loaded with specific peptides
(YMDGTMSQV for the Tyr-TCR, ELAGIGILTV for the MART-1-
TCR, orALYVDSLFFL for the PRAME-TCR).NKTs andCD8þTcells
were stimulated with PMA (25 ng/mL), ionomycin (1 mg/mL; both
from Sigma-Aldrich), and IL2 (100 IU/mL) as a positive control. After
18 hours, IFNg single-forming cells (SFC) were counted using the
ELISpot reader (AIDClassic ELR07) and analyzed using the Elispot7.0
software.
Study approval
All mouse experiments were performed in accordance with UNC
AnimalHusbandry and Institutional Animal Care andUseCommittee
(IACUC) guidelines and were approved by UNC IACUC (IACUC ID:
49268).
Xenograft models
Female and male NSG mice (7–9 weeks of age, obtained from the
UNC Animal Core) were injected either subcutaneously (s.c.) with
0.5 106 SK-MEL-5 tumor cells or intravenously (i.v.) via tail injection
with 0.5–1  106 FFluc-labeled M14-wt or M14-A2 tumor cells. In
specific experiments, mice received low-dose irradiation (100 cGy)
24 hours before receiving i.v. 1  106 FFluc-labeled M14-A2 cells.
Seven days after tumor cell injection (day 0) and at daysþ5 andþ12,
mice were infused i.v. with 1  107 or 5  106 nontransduced (NT)-
NKTs or Tyr-TCR NKTs (expressing or not eGFP-FFluc, and non-
sorted for TCR expression). In selected experiments, nontransduced
(NT)-T cells and T cells expressing the Tyr-TCR (Tyr-TCR-Ts and
nonsorted for TCR expression) were also used. In selected experi-
ments, recombinant human IL2 (1000 U/mouse) was administered
intraperitoneally (i.p.) every 2 days for a total of 8 doses after the
were incubated with medium alone or in 1% Triton X-100 (Sigma-
Aldrich) to determine the spontaneous and maximum 51Cr release, 
respectively. The mean percentage of specific lysis of triplicate wells 
was calculated as follows: [(test counts  spontaneous counts)/(max-
imum counts  spontaneous counts)]  100%.
Confocal microscopy
SupT1 cells and NKTs were prepared according to the manufac-
turer's instructions (Abcam immunofluorescence protocol). Briefly, 
cells were fixed with cytofix buffer (BD Biosciences) and permeabilized 
with 0.1% Triron X in PBS. Cells were then incubated with anti-
Va24Ja18 (clone 6B11, Novus Biologicals) diluted at 1:800 in PBS/1%
BSA. The Alexa Fluor 546 goat anti-mouse IgG1 (Invitrogen) diluted at 
1:500 in PBS/1% BSA was used as a secondary Ab. Cells were mounted 
cover slips with one drop of ProLong Diamond Antifade Mountant 
with DAPI (Invitrogen). Data acquisition was performed on LSM700 
Zeiss confocal microscopy using ZEN software (ZEISS Microscopy). 
Data analysis was performed with Fiji software.
TCR repertoire profiling/TCR amplicon sequencing
DNA or RNA were extracted from sorted NKTs using the Qiagen 
DNeasy or RNeasy micro kits. NKT receptor b chain libraries were 
prepared using the Clontech SMARTer Human TCR a/b profiling kit, 
according to the manufacturer's protocol. Libraries were sequenced via 
2  150 paired end on an Illumina MiSeq at the UNC High-
Throughput Sequencing Facility. TCR variable chain calling was 
performed using IMGT/HighV-QUEST, with subsequent analyses 
performed using the tcR R package (25).
Real-time qPCR
iTCR and Tyr-TCR expression and integration were measured in 
NKTs by qPCR with specific primers and probes and normalized to the 
18S gene expression. Briefly, RNA was extracted from NKTs (RNeasy 
Plus Kit, Qiagen), and 1 mg of RNA was used for reverse transcription 
(5X VILO Reaction Mix and 10X SuperScript Enzyme Mix from 
Invitrogen). For the qPCR reaction (TaqMan 2X Universal PCR 
Master Mix from Life Technologies), 20 ng of cDNA were ran 
in duplicates. The relative expression was calculated as follows: 
2 [(CTgene – CT18S) – CTVa24 in NT-NKTs]. DNA was extracted from 
NKTs (DNeasy Blood and Tissue Kit, Qiagen) and 500 ng of DNA was 
used for the qPCR reaction. To calculate the number of copies of Tyr-
TCR construct in NKTs post sorting, we created a standard curve with 
the SFG Tyr-TCR plasmid and the QuantStudio Real-Time PCR 
software automatically calculated the number of copies/100 ng DNA. 
Data acquisition was performed on a QuantStudio 6 Flex from Life 
Technologies using the QuantStudio Real-Time PCR software. The 
primers and probe for the 18S (Hs03003631_g1) were purchased from 
Thermo Fisher Scientific. Va24 primers: Forward 50-TGTCAAGCT-
GGTCGAGAAAAG-30 Reverse: 50-TCATGAGCAGATTAAACC-
CGG-30 Probe 50-CCACTTTCAGGAGGAGGATTCGGAAC-30. 
Tyr-TRAC primers: Forward 50-ACTTCGACAGCCAGATCAAC-
3 0 Reverse: 5 0-TGTGAAGCTGGTCTGATTG -3 0 Probe 50-
TGCTGGACATGAAGGCGATGGA-30. Tyr-TRBC primers: For-
ward 50-TGGGTCAACGGCAAAGAG-30 Reverse: 50-TGGCATCT-
GAAGTGGTTCC -30 Probe 50-CCGATCCCCAGGCCTACAAA-
GAG-30.
Western blot
Three million tumor cells (M14-wt, M14-A2, C8161, or SK-MEL-5) 
were lysed with 81 mL of 2X Laemmil Sample Buffer (Bio Rad) and 9 mL 
of 2-mercaptoethanol (Fisher Scientific). Ten microliters of total
observed when NKTs were transduced with gamma retroviral vectors
encoding other HLA-A2–restricted TCRs specific for survivin (Sur-
TCR), PRAME (PRAME-TCR), and MART-1 (MART-1-TCR) anti-
gens (Supplementary Fig. S1A), thus excluding that the observed
emergence of CD3þiTCR NKTs was an exclusive phenomenon
caused by the Tyr-TCR. Staining with iTCR and Tyr-TCR multimers
revealed three distinct cell subsets: iTCRTyr-TCRþ (44%  15%),
iTCRþTyr-TCRþ (34%  11%), and iTCRþTyr-TCR (19%  11%)
cells. These three subsets were also identified when using other
combinations of Abs (Va24, Vb11, and Vb12 Abs) recognizing
Tyr-TCR and iTCR (Fig. 2B). Using SupT1 cells (CD3þTCR; ref. 26),
we observed that ectopic TCRs outcompeted iTCRs for cell-surface
expression (Supplementary Fig. S1B) and that iTCRs were retained
within the cytoplasm (Supplementary Fig. S1C). When iTCRþTyr-
TCRþ and iTCRTyr-TCRþNKTs were sorted, the Va24 chain of the
iTCR was detectable in both subsets by confocal microscopy but was
confined to the cytoplasm in iTCRTyr-TCRþ NKTs, whereas it was
expressed on the cell surface in iTCRþTyr-TCRþ NKTs (Fig. 2C).
Based on these results, we hypothesized that in iTCRTyr-TCRþ
NKTs, the Tyr-TCR displaced the iTCR for CD3 usage, and as a
consequence, it was preferentially transferred to the cell surface. To
corroborate this premise, we transduced NKTs with a retroviral vector
encoding the CD3gdez genes (6) to provide an excess of CD3 toNKTs,
and confirmed an increase of CD3 molecules on the cell surface
(Fig. 2D). When Tyr-TCR NKTs were transduced with the CD3
encoding vector, we observed an increase of the iTCRþTyr-TCRþ
subset (from 34%  14% to 72%  3%, gated on Tyr-TCRþ cells, P <
0.0001; Fig. 2E). Overall, these data indicated that the ectopic TCR can
displace the iTCR from CD3 binding in NKTs.
Higher transcripts of the ectopic TCR outcompete the
endogenous iTCR
We then studied how the transgenic TCR displaces the endogenous
iTCR in NKTs. We first analyzed if iTCRþTyr-TCRþ and iTCRTyr-
TCRþ subsets showed differences in coreceptor expression, but both
CD4 and CD8 were equally distributed within the two subsets
(Fig. 3A). Although the Va24-Ja18 chain is known to preferentially
pair with Vb11 (TRBV25-1) chains in humanNKTs (16), we explored
if combination with distinct Vb chains correlated with the specific
NKTs subsets. iTCRþTyr-TCRþ and iTCRTyr-TCRþ were sorted
using specific TCR multimers (Supplementary Fig. S2A) and subse-
quently analyzed for TCRb using RNA amplicon sequencing.
Although TRBV25-1 was the dominant detected TCR Vb chain
(range, 90.54%–96.49%), a proportion of the repertoire was distributed
across the other 47 Vb chains (Fig. 3B). However, TCR Vb chain
distribution was conserved between iTCRþTyr-TCRþ and iTCRTyr-
TCRþ subsets, suggesting that the TCR Vb repertoire differences did
not segregate for iTCR expression. The majority of shared TCR clones
(identified by theCDR3 sequence of theVb chain)was observedwithin
each donor rather than within the iTCRþTyr-TCRþ or iTCRTyr-
TCRþ subsets (Supplementary Fig. S2B), indicating that the type of
TCR Vb chain associated with the Va24-Ja18 was not affecting the
binding with CD3, and thus the iTCR displacement in iTCRTyr-
TCRþ NKTs.
We next reasoned that the iTCR expression may be associated with
transgene integrant copy-number variations between the iTCRþTyr-
TCRþ and iTCRTyr-TCRþ subsets. We assessed the mRNA expres-
sion of bothTyr-TRACandTyr-TRBC chains (transgenic TCR) and of
Va24 (iTCR) in both iTCRþTyr-TCRþ and iTCRTyr-TCRþ subsets
and found the mRNA of both Tyr-TCR chains to be significantly
higher than the mRNA expression of the iTCR chain (Fig. 3C). Both
adoptive transfer of either NKTs or T cells. Melanoma tumor cell 
growth was monitored weekly either with caliper measurement for s.c. 
tumors, or by bioluminescence (BLI; total flux, photons/second) using 
the IVIS kinetic in vivo imaging system (PerkinElmer) for the met-
astatic models. Mice were sacrificed according to UNC guidelines for 
either tumor growth or occurrence of sign of discomfort, including 
graft-versus-mouse disease (weight loss, fur loss, and lethargy). When 
mice were sacrificed, peripheral blood was collected from the heart and 
spleen, liver, and tumor were smashed on cell strainers and washed 
with 2 mL of PBS. Peripheral blood, spleen, liver, and tumors were 
analyzed to detect the presence of NKTs or T cells [stained with Abs 
against CD3 (APC-H7, clone SK7) and CD45 (APC, clone 2D1)] by 
flow cytometry using CountBright absolute counting beads (Invitro-
gen). In selected experiments, tumors were isolated, homogenized in a 
total of 1 mL of PBS, and 100 mL of the supernatant were used to 
measure the human IFNg using the DuoSet Human IFNg ELISA kit 
(R&D Systems). Infiltrating NKTs were counted in the tumors by 
staining with Abs against CD3 (APC-H7, clone SK7) and CD45 (APC, 
clone 2D1) and counting beads (Invitrogen) and analyzing via flow 
cytometry.
Statistical analysis
Data were summarized as the mean  SD. Student t test or two-way 
ANOVA were used to determine statistically significant differences 
between treatment groups, with Bonferroni's correction for multiple 
comparisons when appropriate (Prism 6: GraphPad Software). Sur-
vival analysis was performed using the Kaplan–Meier method (Prism 
6: GraphPad Software). All P values less than 0.05 were considered 
statistically significant.
Results
NKTs can be engineered to express an ectopic TCR
Isolated and cultured NKTs (Fig. 1A) robustly and consistently 
expanded ex vivo (fold increase: 17  4 after the first stimulation, 
S1; Fig. 1B). By days 5 to 7 of culture (before retroviral transduction), 
93%  4% of the isolated cells expressed the iTCR, as assessed by flow 
cytometry using a specific tetramer (Fig. 1B). As a proof of concept, 
NKTs were transduced with a gamma retroviral vector to express an 
HLA-A2–restricted, tyrosinase-specific TCR (Tyr-TCR; ref. 19). Tyr-
TCR was detectable in 76%  8% NKTs (Tyr-TCR NKTs), and the 
expression remained stable over the course of the entire culture period 
(Fig. 1C). The growth kinetics of NKTs was not hampered by the 
expression of the Tyr-TCR, as 1.2  108  8.5  107 cells were obtained 
at the end of the culture period (S2), a number that is sufficient for 
clinical adoptive transfer (Fig. 1D). Tyr-TCR NKTs retained the 
phenotypic characteristics of nontransduced NKTs, including pres-
ervation of CD4 and CD8 composition and expression of CD62L and 
exhaustion markers (Fig. 1E). Tyr-TCR NKTs showed HLA class I 
restriction, as they lysed HLA-A2þ PHA blasts loaded with the HLA-
A0201 tyrosinase YMD peptide (77%  28% lysis at the E:T ratio of 
40:1), whereas control NKTs (NT-NKTs) showed negligible cytotoxic 
activity (Fig. 1F). Overall, NKTs could be successfully manipulated to 
express a functional MHC class I–restricted TCR.
An ectopic TCR displaces the iTCR for expression on the cell 
surface in NKTs
As early as 3 to 4 days after retroviral transduction with the Tyr-
TCR–expressing vector, Tyr-TCR NKTs consisted of two distinct 
subsets, namely, CD3þiTCRþ (59%  18%) and CD3þiTCR (41% 
 18%) cells (Fig. 2A). A similar downregulation of the iTCR was
line SK-MEL-5. The HLA-A2þTyr melanoma cell line C8161 was
used as a negative control. As additional controls, we tested the
melanoma cell line M14 that is HLA-A2Tyrþ (M14-wt) and the
same cell line genetically modified to express the HLA-A2 molecule
(M14-A2; Fig. 4A). Tyr-TCR NKTs consistently lysed the HLA-
A2þTyrþ M14-A2 and SK-MEL-5 cells but not the HLA-A2Tyrþ
(M14-wt) or HLA-A2þTyr (C8161) tumor cells (Fig. 4B). Both
iTCRþTyr-TCRþ and iTCRTyr-TCRþ NKT subsets lysed the
M14-A2 and SK-MEL-5 cells (Supplementary Fig. S3A). We then
cocultured Tyr-TCR NKTs and control NT-NKTs with these mela-
noma cell lines for 3 days. Both M14-A2 and SK-MEL-5 cells were
efficiently eliminated (<3% residual tumor cells) by Tyr-TCR NKTs,
whereas M14-wt and C8161 cells overgrew and accounted for more
than 85% of the cells at the end of the 3-day culture (Fig. 4C). NT-
NKTs did not eliminate any of these tumor cells. The antitumor
activity of Tyr-TCR NKTs was paralleled by IFNg production, which
was detected only whenTyr-TCRNKTswere coculturedwithM14-A2
and SK-MEL-5 cells (Fig. 4D). The IFNg production in response to
melanoma cell lines was comparable in both iTCRþTyr-TCRþ and
iTCRTyr-TCRþ NKT subsets (Supplementary Fig. S3B). Overall,
these data demonstrated the antitumor activity of NKTs genetically
modified to express an HLA-A2–restricted TCR.
Figure 1.
NKTs can be genetically modified to express an HLA-A2–restricted tyrosinase-specific TCR (Tyr-TCR). A, Schematic timeline of the protocol used to select,
transduce, and expand NKTs. S1 and S2 indicate the first and second stimulation, respectively. B, Fold increase (left), representative flow cytometry
plots (middle), and purity of NKTs (right) on days 5 to 7 after S1 (n ¼ 10, mean shown). C, Representative flow cytometry plots (left) and summary (right)
of Tyr-TCR expression by control (NT-NKTs) and transduced (Tyr-TCR NKTs) NKTs assessed at day 19 of culture (n ¼ 10, mean shown).  , P < 0.0001,
paired t test. D, Total cell numbers of NT-NKTs and Tyr-TCR NKTs at day 19 (n ¼ 10, mean þ SD shown). E, Phenotypic characterization of NT-NKTs and
Tyr-TCR NKTs at days 19 to 20 of culture (n ¼ 6, mean shown). F, NT-NKTs and Tyr-TCR NKTs were tested in a 5-hour 51Cr-release assay against different
ratios of HLA-A2þ PHA blasts loaded with either the specific tyrosinase peptide (YMD) or an irrelevant MART-1 peptide (Irrel, ELAGIGLTV) at the concentration
of 100 nmol/L (n ¼ 4, mean þ SD shown).
Tyr-TCR chains were more significantly expressed in iTCRTyr-
TCRþ cells than in the iTCRþTyr-TCRþ subset (P ¼ 0.0004; 
Fig. 3C). The higher mRNA expression of Tyr-TRAC and Tyr-
TRBC chains in iTCRTyr-TCRþ NKTs reflected the higher copy 
numbers of the transgene integrants (Fig. 3D). We then analyzed 
the functionality of sorted iTCRþTyr-TCRþ and iTCRTyr-TCRþ 
NKTs and found that it was independent from the expression 
of the iTCR because only the iTCRþTyr-TCRþ subset released 
IFNg in response to the agonistic Va24 mAb (clone 6B11; 
Fig. 3E), but both iTCRþTyr-TCRþ and iTCRTyr-TCRþ subsets 
lysed and produced IFNg in response to HLA-A2þ PHA blasts 
loaded with the HLA-A0201–restricted YMD peptide (Fig. 3F). 
Overall, these data suggest that the ectopic TCR outcompeted the 
iTCR for CD3 binding when the a- and b-TCR chains were 
expressed at higher levels than iTCR chains, so that the HLA-
restricted cytotoxic activity of TCR NKTs could be exploited 
regardless of the presence of the iTCR on the cell surface.
Tyr-TCR NKTs acquire HLA-A2–restricted cytotoxic activity 
against tumor cells
To measure the antitumor activity of Tyr-TCR NKTs against tumor 
cells expressing tyrosinase, we used the HLA-A2þTyrþ melanoma cell
High-functional avid TCRs are required to generate TCR-
redirected NKTs
To assess if TCR avidity played a role in determining the anti-
tumor activity of TCR-redirected NKTs, we used NKTs expressing
an HLA-A2–restricted MART-1–specific TCR (MART-1-TCR),
which is characterized by lower functional avidity compared with
the Tyr-TCR (19). Transduction of NKTs with MART-1–TCR was
comparable with that of Tyr-TCR (75%  13% vs. 78%  10%,
respectively; Fig. 5A) and also in terms of expression [MART-1–
TCR mean fluorescence intensity (MFI) ¼ 22,377  1,753 vs.
Tyr-TCR MFI ¼ 19,461  2,336; Supplementary Fig. S4A].
However, MART-1–TCR NKTs had less IFNg spot-forming cells
against T2 cells loaded with decreasing concentrations of the
specific peptide compared with Tyr-TCR NKTs (Fig. 5B), despite
TCRs being expressed at comparable levels. Similarly, MART-1–
TCR NKTs showed lower cytotoxic activity against HLA-A2þ
PHA blasts loaded with the specific peptide than Tyr-TCR NKTs
(Fig. 5C). In contrast, when expressed in CD8þ T cells, both
Tyr-TCR and MART-1–TCR (Fig. 5D) showed similar func-
tionality to one another, assessed by IFNg SFCs in response to
peptide-loaded T2 cells (Fig. 5E) and cytotoxic activity against
peptide-loaded HLA-A2þ PHA blasts (Fig. 5F). We also compared
the antitumor activity of Tyr-TCR– and MART-1-TCR–expressing
T cells and NKTs against the SK-MEL5 cell line, which expresses
both tyrosinase and MART-1 (Fig. 5G). Although CD8þ T cells
expressing either the Tyr-TCR or MART-1–TCR eliminated
HLA-A2þTyrþMART-1þ melanoma cells in coculture experiments
(Fig. 5H), only Tyr-TCR NKTs successfully eliminated these tumor
cells (Fig. 5I). These data were confirmed using another low-affinity
HLA-A2-restricted TCR specific for PRAME (PRAME-TCR). As
observed for the MART-1-TCR, despite comparable transduction
efficiency and MFI (Supplementary Fig. S4B), PRAME-TCR-NKT
Figure 2.
Transgenic TCRs outcompete the iTCR for expression on the cell surface in NKTs. A, Representative flow cytometry plots (left) and summary (right) illustrating
the expression of the iTCR in NT-NKTs and Tyr-TCR NKTs 4 days after transduction (n ¼ 10, mean shown).  , P < 0.0001, paired t test. B, Subset composition of
NT-NKTs and Tyr-TCR NKTs at the end of S2 (days 18–20) defined by expression of iTCR and Tyr-TCR detected by specific pentamers (n ¼ 10, left, SD
shown). Representative flow cytometry plots illustrating the expression of the iTCR (stained alternatively with the iTCR tetramer, anti-Va24, or anti-Vb11),
and the Tyr-TCR (stained with either the Tyr-TCR pentamer or anti-Vb12; right). C, Surface and intracellular staining of sorted iTCRþTyr-TCR, iTCRTyr-TCRþ,
and iTCRþTyr-TCRþ NKT subsets with the Va24Ja18 Ab (red staining). The blue staining indicates the DAPI. Shown are representative images of a single field of
view taken via confocal microscopy (magnification, 63). Graphs show the summary of the mean fluorescence intensities (MFI) for surface and intracellular
staining (n ¼ 50, right, mean shown). MFI was calculated on NKTs obtained from 4 images for each condition.  , P < 0.0001, unpaired t test. D, Number of
CD3 molecules per cell in control NKTs (NT) and NKTs transduced with a vector encoding the CD3 complex (trCD3; n¼ 4, mean shown).  , P¼ 0.0151, paired t test.
E, Representative flow cytometry plots (left) and summary (right) illustrating the percentage of iTCRTyr-TCRþ and iTCRþTyr-TCRþ cells gated on Tyr-TCRþ
NKTs, in NKTs transduced with the Tyr-TCR encoding vector alone (Tyr-TCR NKTs) and in NKTs cotransduced with the vectors encoding the Tyr-TCR and CD3
(Tyr-TCR-trCD3 NKTs; n ¼ 5, SD shown).
Tyr-TCR NKTs provide antitumor effects in vivo
Having shown that functional avid Tyr-TCR grants the antigen
specificity of NKTs in vitro, we used a xenogeneic NSG melanoma
mouse model to assess if Tyr-TCR NKTs controlled tumor growth
in vivo. NKTs were administered i.v. in mice engrafted s.c. with
the melanoma cell line SK-MEL-5 (Fig. 6A). Tyr-TCR NKTs
exhibited superior control of tumor growth than NT-NKTs
(317 mm3  124 mm3 vs. 1121 mm3  216 mm3, respectively, at
day 64, P < 0.0001; Fig. 6B; Supplementary Fig. S6A). None of the
NKT-treated mice developed signs of graft-versus-mouse toxicity.
In harvested tumors, we observed a higher number of infiltrating
NKTs in mice treated with Tyr-TCR NKTs compared with
NT-NKTs (997  650 NKTs vs. 351  401 NKTs, respectively)
and higher detection of IFNg release (183.5 pg/mL  179.1 pg/mL
vs. 12.1 pg/mL  13.7 pg/mL, respectively; Fig. 6C), suggesting that
Figure 3.
Tyr-TCR function inNKTs does not require the presence of the iTCR.A,CD4/CD8 composition in each subset of Tyr-TCRNKTs (n¼ 3, SD shown).B,Frequency of TCR
Vb chain RNA in NT-NKTs, iTCRþTyr-TCRþ NKTs, and iTCRTyr-TCRþ NKTs obtained after sorting and TCR amplicon RNA sequencing of each subset (SD shown).
C, Relative expression of the TCR Va24 chain for the iTCR, and of TCRa (Tyr-TRAC) and TCRb (Tyr-TRBC) chains for Tyr-TCR assessed by qPCR in NT-NKTs,
iTCRþTyr-TCR, iTCRþTyr-TCRþ, and iTCRTyr-TCRþNKT subsets (n¼ 6, mean shown).  , P¼ 0.0004 for Tyr-TRAC;  , P¼ 0.0002 for Tyr-TRBC, paired t test.
D, Quantitation of TCRa (Tyr-TRAC) and TCRb (Tyr-TRBC) copy number of integrated transgene via qPCR in NT-NKTs, iTCRþTyr-TCRþ, and iTCRTyr-TCRþ
NKT subsets (n¼ 5, mean shown).  , P¼ 0.0087 for Tyr-TRAC;  , P¼ 0.0062 for Tyr-TRBC, paired t test. E, Quantification of IFNg in supernatants collected after
24 hours from the activation of NT, iTCRTyr-TCRþ, and iTCRþTyr-TCRþNKTswith the Va24 Ab. Isotype control was used as negative control (n¼ 5, mean shown).
 , P¼ 0.0139, paired t test. F, iTCRTyr-TCRþ and iTCRþTyr-TCRþ NKTs were tested in a 5-hour 51Cr-release assay (E:T¼ 40:1) against HLA-A2þ PHA blasts loaded
with an irrelevant MART-1 peptide (Irrel, ELAGIGLTV) or with the YMDpeptide (100 nmol/L; left; n¼ 4,mean shown). Quantification of IFNg in supernatants collected
after 24 hours from the cocultures (E:T¼ 1:1) of iTCRTyr-TCRþor iTCRþTyr-TCRþNKTswithHLA-A2þPHAblasts loadedwith an irrelevant peptide (Irrel) orwith the
YMN peptide (100 nmol/L; right; n ¼ 4, mean shown).
functions were inferior to those of PRAME-TCR-Ts, as the former  
had less IFNg SFCs against T2 cells loaded with decreasing con-
centrations of the specific peptide (Supplementary Fig. S4C) and 
showed an inferior cytotoxic activity against peptide-loaded HLA-
A2þ PHA blasts (Supplementary Fig. S4D).
Because CD8þ T cells expressing either MART-1-TCR or Tyr-
TCR were equally effective, we explored if the functionality of 
MART-1-TCR NKTs, that were mostly CD4þ or CD4CD8 
cells, could be rescued by overexpressing the CD8a subunit, as 
previously reported for CD4þ T cells (27). Coexpression of both a 
MART-1-TCR and human CD8a (>60% CD8aþ), this modifica-
tion failed to enhance the functional avidity of MART-1-TCR 
NKTs (Supplementary Fig. S5A–S5C). Thus, our data suggest that 
the intrinsic functional avidity of the TCR was critical to func-
tionally redirect NKT activity via HLA class I–restricted TCRs.
Tyr-NKTs were functional at the tumor site. In contrast, no
difference in the numbers of Tyr-TCR NKTs and NT-NKTs was
detected in peripheral blood, liver, and spleen, and the expression of
the Tyr-TCR was detectable in all the Tyr-TCR NKTs isolated
(Supplementary Fig. S6B and S6C).
To further assess in vivo the HLA restriction of the antitumor
responses mediated by Tyr-TCRNKTs, we also generated a metastatic
murine model in which NSG mice were injected i.v. with either M14-
wt orM14-A2 cells modified to express the enhanced green fluorescent
protein (eGFP) and the firefly luciferase gene (FFLuc or eGFP-FFLuc).
Tumor bioluminescence (BLI) was reduced only in mice engrafted
with M14-A2 cells and treated with Tyr-TCR NKTs (P < 0.0001;
Fig. 6D). When euthanized between days 41 and 63, the number of
liver tumor metastases in M14-A2 tumor–bearing mice was signifi-
cantly reduced compared withM14-wt tumor–bearing mice (1 2 vs.
30  13, P < 0.0001; Fig. 6E). In the same mouse model, we also
assessed in vivo the persistence of Tyr-TCR NKTs using NKTs label-
ed with eGFP-FFLuc and unlabeled tumor cells. Tyr-TCR NKT BLI
was detectable for 7 days after infusion (Fig. 6F). NKT persistence was
also corroborated by phenotypic analyses in the peripheral blood and
spleen (1.6%  0.2% and 0.9  1.2% hCD3þhCD45þ cells, respec-
tively) of treatedmice (Fig. 6G). To assess if Tyr-TCRNKTs produced
Figure 4.
Tyr-TCR NKTs target HLA-A2þTyrþ cells. A, Expression of the HLA-A2 molecule in melanoma cell lines assessed by flow cytometry (left). Dotted and solid lines
represent the isotype and HLA-A2 mAbs, respectively. The M14-wt cell line was modified to express the HLA-A2 molecule (M14-A2) via retroviral gene transfer.
Detection of tyrosinase in lysates of the indicatedmelanoma cell lines assessed byWestern blot (right). Staining for b-actinwas used as a loading control.B,NT-NKTs
(top graph) and Tyr-TCRNKTs (bottom graph)were tested against themelanoma cell lines in a 5-hour 51Cr-release assay (n¼ 4,meanþ SD shown).  , P <0.0001,
two-wayANOVAwith Bonferroni correction.C,NT-NKTs and Tyr-TCRNKTswere coculturedwithmelanoma cell lines (E:T¼ 1:1) for 3 days. Cells were then collected
and stainedwith theCD3 andCD276mAbs to identify NKTs andmelanomacells, respectively, by flowcytometry. Representative flowplots (left) and summary of the
quantification of residual tumor cells in the culture (right, n¼ 5, mean shown). , P < 0.0001, paired t test. D,Quantification of IFNg production in the supernatant
collected after 24 hours of coculture of NT-NKTs and Tyr-TCR NKTs (E:T ¼ 1:1; n ¼ 4, mean shown).  , P < 0.0001, paired t test.
term tumor control mediated from the Tyr-TCR-Ts. Finally,
we used the same in vivo models, but decreased the number of
T cells and NKTs injected (5  106 cells/injection; Supplementary
Fig. S7A). The antitumor activity of Tyr-TCR NKTs and Tyr-TCR-Ts
treated mice was comparable (Supplementary Fig. S7B–S7D), and the
Tyr-TCR-Ts continued to cause a lethal graft-versus-mouse effect
(Supplementary Fig. S7E). Thus, our data indicated that TCR NKTs
could control tumor growth in vivo without causing reactivity against
murine tissues.
Discussion
We showed that the antigen specificity of human NKTs could be
redirected toward tumor antigens by inserting an ectopic TCR. Our
study critically outlined the advantages of using this platform for the
expression of ectopic TCRs, namely, how the TCR could outcompete
Figure 5.
A high-affinity TCR is required to redirect NKT specificity. Expression of Tyr-TCR and MART-1-TCR in NKTs (A) and CD8þ T cells (D), assessed with an Ab specific
for the TCR Vb12 chain, 3 days after transduction (n ¼ 6, mean shown). NT-NKTs and NT-CD8þ T cells were also used as controls. TCR functional avidity assessed
by IFNg ELISpot assays for Tyr-TCR and MART-1-TCR in NKTs (B) and CD8þ T cells (E) against T2 cells loaded with decreasing concentrations of the specific peptide
(left graphs). T2 cells loaded with an irrelevant peptide or PMA/ionomycin/IL2 (þctr) were used as negative and positive controls, respectively (right graphs, n¼ 5,
meanþSEMshown).  ,P<0.0001, two-wayANOVAwithBonferroni correction. SFCs, spot-forming cells. Cytotoxic activity assessed in a 5-hour 51Cr release assay
for NT, Tyr-TCR, and MART-1-TCR NKTs (C) and CD8þ T cells (F) against HLA-A2þ PHA blasts pulsed with either the specific peptide or an irrelevant peptide
(Irrel, ELAGIGLTV) at the concentration of 100 nmol/L (n ¼ 5, mean þ SD shown).  , P < 0.0001 by two-way ANOVA with Bonferroni correction. G, Detection
of MART-1 in lysates of melanoma cell lines assessed by Western blot. Staining for b-actin was used as a loading control. NT, Tyr-TCR, and MART-1-TCR CD8þ
T cells (H) and NKTs (I) were cocultured with SK-MEL5 or C8161 (E:T¼ 1:1) for 3 days. Cells were then collected and stained with the CD3 and CD276 Abs to identify
NKTs/CD8þ T cells and tumor cells, respectively, by flow cytometry. Quantification of the residual tumor cells in the culture (n ¼ 3, mean shown).  , P < 0.0001,
paired t test.
superior antitumor control when their persistence was prolonged, we 
infused multiple doses of Tyr-TCR NKTs and compared the efficacy of 
Tyr-TCR NKTs and Tyr-TCR-Ts generated from the same donors 
(Fig. 7A). Both Tyr-TCR NKTs and Tyr-TCR-Ts, which were detect-
able in the circulation up to days 40 to 60 (Fig. 7B), successfully 
controlled tumor growth (Fig. 7C and D) and produced an improved 
overall survival compared with NT-NKTs and NT-Ts (P < 
0.0001; Fig. 7E). The number of liver tumor metastases was signif-
icantly reduced in mice treated with either the Tyr-TCR NKTs or the 
Tyr-TCR-Ts compared with NT-NKTs and NT-Ts (P < 0.0001; 
Supplementary Fig. S6D). Tyr-TCR NKTs and Tyr-TCR-Ts were 
detectable in both the liver and spleen of mice sacrificed between 
days 40 and 60 (Supplementary Fig. S6E). However, 11 of the 18 mice 
(61%) receiving Tyr-TCR-Ts developed lethal graft-versus-mouse 
disease characterized by weight and fur loss and lethargy (Fig. 7F). 
This graft-versus-mouse disease also confounded the observed long-
the iTCR for the cell-surface expressionwithout the need for additional
manipulation to knockdown endogenous TCR chains as required in
T cells.
Adoptive transfer of polyclonal T cells expressing high-affinity
TCRs have shown promising clinical responses (28). However, current
issues related to ectopic TCR expression in T cells suggest that
exploring alternative platforms for TCR expression may be beneficial
to further enhance clinical activity and safety of TCR-engineered cells.
We previously demonstrated that NKTs can be engineered to express a
chimeric antigen receptor for redirected tumor target capabilities (29).
Jiang and colleagues previously showed that an HLA class I–restricted
TCR targeting an epitope of the 38-kDa protein of theMycobacterium
tuberculosis can be expressed by NKTs and react against DCs pulsed
with the 38-kDa protein (30). However, redirecting NKTs for the
targeting of tumor cells via HLA class I restriction has so far remained
unexplored.
Here, we have shown that NKTs expressing an ectopic HLA class
I–restricted TCR can be generated in less than 3 weeks of culture,
and in sufficient numbers for the clinical translation. We showed
that the ectopic TCR can displace the iTCR on a proportion of
NKTs by outcompeting for binding to the CD3 complex. This
phenomenon occurred when the mRNA of the ectopic TCR chains
was overexpressed compared with the endogenous iTCR, with
higher transcript numbers dictating which receptor was expressed
on the cell surface of NKTs. Interestingly, Sommermeyer and
colleagues previously showed that a transgenic TCR can outcom-
pete the endogenous TCR in CMV-specific T-cell clones (31). Our
study, thus, underlines that the restricted TCR repertoire of
Figure 6.
Tyr-TCRNKTs control thegrowthof HLA-A2þTyrþ cells in vivo.A,Schemaof the xenograft tumormodel inNSGmiceengrafted s.c.with SK-MEL-5 cells or i.v.withM14
cells and treated 1 week later with NKTs. B, Tumor growth in mice engrafted s.c. with SK-MEL-5 tumor cells and treated with NT-NKTs (n¼ 5) or Tyr-TCR NKTs (n¼
10). Dotted lines represent individual mice, and bolded solid lines represent the mean for the group.  , P < 0.0001, two-way ANOVA with Bonferroni correction.
C,Quantification of human CD3þCD45þ cells (left) and IFNg (right) in each tumor harvested frommice engrafted with SK-MEL-5 tumor cells and treated with either
NT-NKTs (n¼ 13) or Tyr-TCR NKTs (n¼ 13; mean shown). , P¼ 0.0055;  , P¼ 0.0021, respectively, unpaired t test. D, Representative tumor BLI (left; color scale:
min ¼ 4.00  106; max ¼ 1.00  108) and BLI kinetics of all treated mice (right) engrafted i.v. with eGFP-FFLuc–labeled M14-wt (n ¼ 3) or M14-A2 (n ¼ 8)
tumor cells.  , P <0.0001, two-wayANOVAwith Bonferroni correction. p/sec or p/s, photons/second. E,Mice engraftedwith eGFP-FFLuc–labeledM14-wt (n¼ 3)
or M14-A2 (n ¼ 8) and treated with Tyr-TCR NKTs were euthanized, and tumor liver metastases counted (left, mean shown). Representative images of the livers
(right).  , P < 0.0001, unpaired t test. F,Mice were infused i.v. with 1 106 M14-wt or M14-A2 cells, and after 7 days, they were injected with 1 107 Tyr-TCR NKTs
labeled with eGFP-FFluc. Representative Tyr-TCRNKTs BLI (left; color scale: min¼ 1.00 106; max¼ 1.00 107) and BLI kinetics of all mice (right) of M14-wt (n¼ 3)
orM14-A2 (n¼4) tumor–bearingmice. p/sec or p/s, photons/second.G,Quantification of human CD3þCD45þ cells in the peripheral blood (P.B.), liver, and spleen
of M14-wt (n ¼ 3) or M14-A2 (n ¼ 3) tumor–bearing mice treated with Tyr-TCR NKTs (mean shown).
significant, considering that, because NKTs are well known for
orchestrating immune responses by inducing maturation of
DCs, activation of T and B cells and transactivation of NK
cells (33–35), our model likely underestimated the real potentials
of TCR NKTs.
Finally, one further advantage of usingNKTs rather than polyclonal
T cells for TCR expression lies in the reduced risk of GvHDwhen both
ectopic and native TCRs are retained by transduced cells. Preclinical
and clinical evidence suggests thatNKTsmay act as negative regulators
of GvHD, making them relevant in the allogeneic context (36–39).
Corroborating these clinical suggestions are previous observations that
CAR-engineered human NKTs do not cause graft-versus-mouse—a
surrogate of GvHD—in NSG mice (29, 37–40). Here, we showed that
TCR NKTs could not only be equally effective as TCR-expressing
T cells in controlling tumor growth, but that, unlike T cells, they did
not cause graft-versus-mouse in NSG mice. Thus, the manipula-
tions needed for appropriate expression of a transgenic TCR and
Figure 7.
Multiple infusions of Tyr-TCR NKTs control tumor growth without inducing graft-versus-mouse effects. A, Schema of the xenograft tumor model in NSG mice
inoculated i.v. with M14 cells and treated with 3 injections of NKTs or T cells (1 107 cells each). B,Quantification of human CD3þCD45þ cells in the peripheral blood
collected 6 to 7 days after each NKT/T-cell infusion and at sacrifice (day > 40; mean shown).  , P < 0.0001, two-way ANOVAwith Bonferroni correction. C and D,
Representative tumor BLI (C; color scale: min¼ 4.00 106;max¼ 1.00 108) and BLI kinetics (D) of all treatedmice in four independent experiments engraftedwith
the eGFP-FFluc–labeled M14-A2 cells and treated with NT-NKTs (n ¼ 15), Tyr-TCR NKTs (n ¼ 15), NT-Ts (n ¼ 15), or Tyr-TCR-Ts (n ¼ 15). Dotted lines represent
individual mice, and bolded solid lines represent the mean for the group. NT-NKTs versus Tyr-TCR NKTs P < 0.0001 at days 28 and 35, two-way ANOVA with
Bonferroni correction. Tyr-TCR NKTs versus Tyr-TCR Ts P < 0.0001 at day 53, two-way ANOVA with Bonferroni correction. p/sec or p/s, photons/second. E,
Kaplan–Meier survival curve (n¼ 15 mice/group);  , P < 0.0001, log-rank test. ns, not significant. F, Graft-versus-mouse (GvM) incidence curve (n¼ 15 mice/
group);  , P < 0.0001, log-rank test.
polyclonal NTKs, compared with the broad TCR repertoire of 
polyclonal T lymphocytes, overcomes the hurdle of gene editing 
required in polyclonal T cells to knockdown the endogenous TCRs 
by granting the displacement of the iTCR.
Independent from the expression of the iTCR, TCR NKTs 
proved to specifically recognize the peptide/HLA-A2 complex and 
exhibited a potent antitumor effect against HLA-A2þ tumor cells 
expressing the targeted antigen. TCR NKTs showed fast killing of 
the target cells and activation as demonstrated by the production of 
IFNg . TCR NKTs maintained their specificity in vivo and mediated 
tumor regression leading to improved overall survival. In partic-
ular, TCR NKTs could control tumor metastasis within the liver. It 
has been reported that murine NKTs can accumulate in the liver of 
mice bearing hepatocellular carcinomas and inhibit the tumor 
growth in both primary and metastatic liver models (32). It remains 
to be demonstrated how human NKTs in NSG mice cause a robust 
antitumor effect  in liver metastases. Our antitumor effects were
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